{"id":"NCT00236938","sponsor":"American Regent, Inc.","briefTitle":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","officialTitle":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-07","primaryCompletion":"2004-09","completion":"2004-10","firstPosted":"2005-10-12","resultsPosted":"2009-09-07","lastUpdate":"2021-05-19"},"enrollment":121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Venofer and stable erythropoietin (EPO) regimen","otherNames":["Iron Sucrose"]},{"type":"DRUG","name":"stable erythropoietin (EPO) regimen","otherNames":["EPO"]}],"arms":[{"label":"Group A","type":"EXPERIMENTAL"},{"label":"Group B","type":"ACTIVE_COMPARATOR"}],"summary":"This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.","primaryOutcome":{"measure":"Mean Change From Baseline to the Highest Hemoglobin up to Day 71","timeFrame":"Change from Baseline up to Day 71","effectByArm":[{"arm":"Group A: Venofer and Erythropoietin EPO Fixed Dose","deltaMin":1.3,"sd":1.1},{"arm":"Group B: Erythropoietin EPO Fixed Dose Only","deltaMin":0.7,"sd":1.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17699248"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":75},"commonTop":["Oedema peripheral","Diarrhea NOS","Hypertension NOS","Catheter site infection","Peritoneal infection"]}}